German Parliament Approves Deep Health-Care Cuts as Insurers Push Prevention Strategy

Bundestag approves €18.8B savings package for 2027, raising co-pays and cutting screenings, as insurers call for prevention-focused strategy.

Just hours before the Bundestag voted on a sweeping cost-saving package, a coalition of company-based health insurers released its own vision for the system’s future. The BKK Dachverband, an umbrella group representing Betriebskrankenkassen, published a policy paper titled “Gönnt uns Gesundheit!” (roughly “Grant Us Health!”) on July 7, 2026. It argues that long-term financial stability depends on a massive prevention drive rather than further benefit reductions.

The parliamentary vote came three days later. On July 10, 2026, the Bundestag passed the GKV-Beitragssatzstabilisierungsgesetz (Statutory Health Insurance Contribution Rate Stabilisation Act) with 319 votes. The Bundesrat gave its approval the same day. The law targets 18.8 billion euros in savings for 2027 – a bid to close a funding gap that government forecasts say could balloon to 40 billion euros by 2030.

For the roughly 73 million people insured under Germany’s statutory system, the changes bite immediately. Co-payments for prescription drugs rise to between 7.50 and 15 euros per item. Skin-cancer screenings and reimbursement for homeopathic treatments are scrapped entirely. The fixed subsidy for dental prosthetics falls from 60 percent to 50 percent of the base cost. And spousal coverage without an extra premium is now limited to couples with children under 12 living in the household.

“We are seeing the limits of a purely budget-driven approach,” said Ulrike Elsner, chair of the Association of Substitute Health Insurance Funds (vdek), also on July 10. She called for structural reforms, especially in primary care and drug pricing, and said the state must stop shifting non-insurance costs onto contributors. The BKK paper echoes that sentiment, urging a modern public-health strategy to cut disease rates and ease long-term cost pressure.

The pharmaceutical industry faces the heaviest immediate hit. The mandatory manufacturer discount jumps from 7 percent to 15.5 percent. Oliver Kirst, head of the German Pharmaceutical Industry Association (BPI), blasted the move as pure cost containment without genuine reform. He cited a 2025 study showing that every euro in mandatory rebates triggers a 3.80-euro loss in economic value, and estimated the sector’s total annual burden at 24–29 billion euros.

Hospitals received modest compensatory measures. The coalition pledged 100 million euros extra for university hospitals and a 450-million-euro invoice surcharge for other clinics to soften the blow from higher rebates and reduced reimbursement.

One unexpected consequence is a surge of interest in company health insurance (betriebliche Krankenversicherung, or bKV). Employers can now pay up to 50 euros per month in premiums tax- and social-security-free under certain conditions, mirroring the model of company pension plans. Workers gain faster access to appointments and services that the reform removed from the standard catalogue. The law also introduces a new tool for occupational health management: partial sick leave, allowing employees to work reduced hours while recuperating.

The contribution assessment ceiling rises by 300 euros in 2027, meaning higher earners will pay levies on a larger slice of their income. The BKK paper, meanwhile, remains outside the binding legislation – a call for future governments to shift the system from reactive treatment to proactive prevention.